JP2018521628A5 - - Google Patents

Download PDF

Info

Publication number
JP2018521628A5
JP2018521628A5 JP2017556597A JP2017556597A JP2018521628A5 JP 2018521628 A5 JP2018521628 A5 JP 2018521628A5 JP 2017556597 A JP2017556597 A JP 2017556597A JP 2017556597 A JP2017556597 A JP 2017556597A JP 2018521628 A5 JP2018521628 A5 JP 2018521628A5
Authority
JP
Japan
Prior art keywords
seq
domain
tag cassette
amino acid
natural killer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017556597A
Other languages
English (en)
Japanese (ja)
Other versions
JP6985934B2 (ja
JP2018521628A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/030281 external-priority patent/WO2016176651A2/en
Publication of JP2018521628A publication Critical patent/JP2018521628A/ja
Publication of JP2018521628A5 publication Critical patent/JP2018521628A5/ja
Priority to JP2021109884A priority Critical patent/JP2021168667A/ja
Application granted granted Critical
Publication of JP6985934B2 publication Critical patent/JP6985934B2/ja
Priority to JP2022199333A priority patent/JP2023036712A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017556597A 2015-04-29 2016-04-29 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用 Active JP6985934B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021109884A JP2021168667A (ja) 2015-04-29 2021-07-01 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用
JP2022199333A JP2023036712A (ja) 2015-04-29 2022-12-14 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562154565P 2015-04-29 2015-04-29
US62/154,565 2015-04-29
PCT/US2016/030281 WO2016176651A2 (en) 2015-04-29 2016-04-29 Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021109884A Division JP2021168667A (ja) 2015-04-29 2021-07-01 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用

Publications (3)

Publication Number Publication Date
JP2018521628A JP2018521628A (ja) 2018-08-09
JP2018521628A5 true JP2018521628A5 (enExample) 2019-11-07
JP6985934B2 JP6985934B2 (ja) 2021-12-22

Family

ID=57198772

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017556597A Active JP6985934B2 (ja) 2015-04-29 2016-04-29 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用
JP2021109884A Pending JP2021168667A (ja) 2015-04-29 2021-07-01 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用
JP2022199333A Pending JP2023036712A (ja) 2015-04-29 2022-12-14 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021109884A Pending JP2021168667A (ja) 2015-04-29 2021-07-01 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用
JP2022199333A Pending JP2023036712A (ja) 2015-04-29 2022-12-14 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用

Country Status (4)

Country Link
US (2) US20180355318A1 (enExample)
EP (2) EP3995142A3 (enExample)
JP (3) JP6985934B2 (enExample)
WO (1) WO2016176651A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014249243C1 (en) 2013-03-13 2019-08-08 Imaginab, Inc. Antigen binding constructs to CD8
SG11201605046YA (en) 2013-12-20 2016-07-28 Hutchinson Fred Cancer Res Tagged chimeric effector molecules and receptors thereof
WO2016176652A2 (en) 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
US11034749B2 (en) 2015-07-28 2021-06-15 The Trustees Of The University Of Pennsylvania Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof
WO2017027325A1 (en) 2015-08-07 2017-02-16 Imaginab, Inc. Antigen binding constructs to target molecules
MX2018004546A (es) 2015-10-16 2019-04-15 Univ Columbia Composiciones y métodos para la inhibicion de antígenos específicos de linaje.
CA3050085A1 (en) 2017-01-20 2018-07-26 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
BR112019017751A2 (pt) 2017-02-28 2020-04-07 Vor Biopharma, Inc. composições e métodos de inibição de proteínas de linhagem específica
CA3071661A1 (en) * 2017-09-06 2019-03-14 Fred Hutchinson Cancer Research Center Strep-tag specific chimeric receptors and uses thereof
CA3082334A1 (en) * 2017-11-20 2019-05-23 Julius-Maximilians-Universitat Wurzburg Cd19cart cells eliminate myeloma cells that express very low levels of cd19
JPWO2020004337A1 (ja) * 2018-06-27 2021-08-02 国立大学法人東海国立大学機構 Ｃｄ３７特異的キメラ抗原レセプター
US11389485B2 (en) 2018-08-28 2022-07-19 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
CA3110858A1 (en) * 2018-08-31 2020-03-05 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods and compositions comprising b7h3 chimeric antigen receptors
US20220127575A1 (en) * 2019-02-09 2022-04-28 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Genetically modified hematopoietic stem and progenitor cells (hspcs) and mesenchymal cells as a platform to reduce or prevent metastasis, treat autoimmune and inflammatory disorders, and rebalance the immune milieu and dysregulated niches
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
WO2021248061A1 (en) 2020-06-04 2021-12-09 Carisma Therapeutics Inc. Novel constructs for chimeric antigen receptors
KR102594083B1 (ko) 2020-07-07 2023-10-25 칸큐어 엘엘씨 Mic 항체 및 결합제 및 이의 사용 방법
CA3172530A1 (en) 2021-02-25 2022-09-01 Spencer PARK Ror1 targeting chimeric antigen receptor
CN114733455B (zh) * 2022-04-15 2023-02-14 北京田园奥瑞生物科技有限公司 一种利用生物改性β-环糊精纳米磁颗粒进行快速哺乳动物精子分型的方法
AU2024244733B2 (en) 2023-03-31 2025-12-11 AbelZeta Inc. Bispecific chimeric antigen receptors targeting cd20 and bcma
CN118853562B (zh) * 2024-07-11 2025-08-29 中国科学院广州生物医药与健康研究院 一种靶向cd19的car-nk细胞及其制备方法和应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3753357A (en) 1970-12-14 1973-08-21 Ovitron Res Corp Method and apparatus for the preservation of cells and tissues
US4199022A (en) 1978-12-08 1980-04-22 The United States Of America As Represented By The Department Of Energy Method of freezing living cells and tissues with improved subsequent survival
US4559298A (en) 1982-11-23 1985-12-17 American National Red Cross Cryopreservation of biological materials in a non-frozen or vitreous state
US5004681B1 (en) 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
US6291161B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
DK0557459T3 (da) 1990-11-13 1997-12-15 Immunex Corp Bifunktionelle, selekterbare fusionsgener
IE20030749A1 (en) 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US5856441A (en) 1991-05-03 1999-01-05 Yale University Serrate fragments and derivatives
IL101728A (en) 1991-05-03 2007-08-19 Univ Yale Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
US5869282A (en) 1991-12-11 1999-02-09 Imperial Cancer Research Technology, Ltd. Nucleotide and protein sequences of the serrate gene and methods based thereon
WO1993012141A1 (en) 1991-12-11 1993-06-24 Yale University Nucleotide and protein sequences of the serrate gene and methods based thereon
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
PT1489097E (pt) 1994-01-11 2012-01-04 Dyax Corp Inibidores de plasmina humana derivados de domínios kunitz e ácidos nucleicos codificando os mesmos
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5877299A (en) 1995-06-16 1999-03-02 Stemcell Technologies Inc. Methods for preparing enriched human hematopoietic cell preparations
ATE442373T1 (de) 1995-06-28 2009-09-15 Imp Cancer Res Tech Nukleotid- und proteinsequenzen von delta-genen von vertebraten und darauf basierende methoden
US5780300A (en) 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
AU781396B2 (en) * 1999-07-20 2005-05-19 Morphosys Ag Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
WO2002059285A1 (en) 2000-10-27 2002-08-01 Fred Hutchinson Cancer Research Center Methods for immortalizing cells
DE10113776B4 (de) 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
EP1400534B1 (en) * 2002-09-10 2015-10-28 Affimed GmbH Human CD3-specific antibody with immunosuppressive properties
US8361794B2 (en) 2004-06-29 2013-01-29 Immunocore Limited Cells expressing a modified T cell receptor
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
ES2538305T3 (es) 2004-10-25 2015-06-18 Cellerant Therapeutics, Inc. Métodos para expandir poblaciones de células mieloides y usos de las mismas
KR20130105885A (ko) 2005-01-05 2013-09-26 에프-스타 비오테크놀로기쉐 포르슝스 운드 엔트비클룽스게스.엠.베.하. 상보성 결정부위와 다른 분자의 부위에서 처리된 결합성을 갖는 합성 면역글로불린 영역
GB0504767D0 (en) 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
US20090220501A1 (en) * 2006-01-30 2009-09-03 Fey Georg H Anti-CD19 Antibody, Immunotoxin and Treatment Method
EP1984491B1 (en) 2006-02-14 2016-12-07 Cellerant Therapeutics, Inc. Compositions for enhancing engraftment of hematopoietic stem cells
EP1829895A1 (en) 2006-03-03 2007-09-05 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
JPWO2007145227A1 (ja) 2006-06-14 2009-11-05 中外製薬株式会社 造血幹細胞増加促進剤
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
CA2700391A1 (en) 2007-09-24 2009-04-02 University Of Zuerich Designed armadillo repeat proteins
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
ES2621181T3 (es) * 2008-11-21 2017-07-03 Lallemand Hungary Liquidity Management Llc Levaduras que expresan celulasas para la sacarificación y fermentación simultáneas utilizando celulosa
SG173654A1 (en) * 2009-02-23 2011-09-29 Glenmark Pharmaceuticals Sa Humanized antibodies that bind to cd19 and their uses
WO2011127472A1 (en) 2010-04-09 2011-10-13 Fred Hutchinson Cancer Research Center Compositions and methods for providing hematopoietic function
JP6165627B2 (ja) 2010-04-09 2017-07-19 フレッド ハッチンソン キャンサー リサーチ センター Ｈｌａの適合なしに造血機能を提供するための組成物および方法
EP2614151B1 (en) * 2010-09-08 2019-07-24 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Interleukin 15 as selectable marker for gene transfer in lymphocytes
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9834755B2 (en) 2011-12-08 2017-12-05 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
EP2970985A1 (en) * 2013-03-14 2016-01-20 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
NZ758715A (en) * 2013-10-31 2023-01-27 Seattle Children’S Hospital Dba Seattle Children’S Res Institute Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
SG11201605046YA (en) * 2013-12-20 2016-07-28 Hutchinson Fred Cancer Res Tagged chimeric effector molecules and receptors thereof

Similar Documents

Publication Publication Date Title
JP2018521628A5 (enExample)
JP2021087455A5 (enExample)
JP2025028239A5 (enExample)
JP2017500009A5 (enExample)
HRP20201906T1 (hr) Označene kimerne efektorske molekule i njihovi receptori
JP2022002546A (ja) 細胞
RU2020135106A (ru) Векторы экспрессии для химерных рецепторов поглощения, генетически модифицированные клетки-хозяева и их применения
RU2019126655A (ru) Нуклеиновые кислоты, кодирующие химерные рецепторы, полипептидные химерные рецепторы, кодируемые ими, векторы экспрессии, содержащие их, выделенные клетки-хозяева, содержащие их, композиции, содержащие выделенные клетки-хозяева, а также способы получения выделенных клеток-хозяев in vitro, способы выбора нуклеиновых кислот, кодирующих химерные рецепторы, in vitro и способы проведения клеточной иммунотерапии у субъекта, имеющего опухоль
JPWO2019191340A5 (enExample)
RU2020135107A (ru) Клеточные иммунотерапевтические композиции и их применения
RU2016121174A (ru) МОДИФИЦИРОВАННЫЕ ГЕМОПОЭТИЧЕСКИЕ СТВОЛОВЫЕ КЛЕТКИ/КЛЕТКИ-ПРЕДШЕСТВЕННИКИ И Не-Т ЭФФЕКТОРНЫЕ КЛЕТКИ, И ИХ ПРИМЕНЕНИЕ
JP2015527070A5 (enExample)
JP2017501702A5 (enExample)
JP2018525033A5 (enExample)
JPWO2019191339A5 (enExample)
CA3016287A1 (en) Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
JP2020517295A5 (enExample)
JP2024023228A5 (enExample)
JP2019527557A5 (enExample)
FI4063397T3 (fi) Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi
JP2018518939A5 (enExample)
JP7319250B2 (ja) Ｓｔｒｅｐ－タグ特異的結合タンパク質およびその使用
US20250236864A1 (en) CAR LIBRARY AND scFv MANUFACTURING METHOD
JPWO2019165116A5 (enExample)
WO2022095801A1 (zh) 靶向lir1的抗体及其用途